ArticleOphthalmology science2026
Correlation between Antiretinal Antibodies and OCT Manifestations in Nonparaneoplastic Autoimmune Retinopathy.
Article in Ophthalmology science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: This study sought to examine the correlation between antiretinal antibodies (ARAs) and OCT manifestations in patients diagnosed with nonparaneoplastic autoimmune retinopathy (npAIR). Design: A retrospective, observational case series. Participants: Fifty-five patients (92 eyes) diagnosed with probable or possible npAIR. Methods: Patients underwent comprehensive evaluation, including best-corrected visual acuity (BCVA), slit-lamp biomicroscopy, fundus photography, autofluorescence, OCT scanning, and electroretinogram. Blood samples were analyzed for the presence of ARAs using Western Blot, including anti-recoverin (ARc), anti-α-enolase (AeNO), anti-carbonic anhydrase II (ACA), and anti-CRMP5 (AC5). Statistical analyses included the Kruskal-Wallis test (logarithm of the minimum angle of resolution BCVA) and 1-way analysis of variance (central retinal thickness [CRT]) for group comparisons. Diagnostic performance of key OCT features was assessed. Main Outcome Measures: Multimodal imaging, BCVA, and CRT of patients diagnosed with npAIR. Results: Among the 55 npAIR patients, 52.7% were positive for a single tested antibody, while 25.5%, 14.5%, and 7.3% had two, three, or four of the tested antibodies, respectively. Central retinal thickness and BCVA were significantly worse in most ARA-positive groups versus controls. However, the AeNO(+) subgroup showed the best-preserved CRT and BCVA. The AeNO(+) eyes predominantly exhibited inner retinal (ganglion cell complex/retinal nerve fiber layer) thinning (66.7%). The ACA(+) and ARc(+) eyes showed patterns of diffuse outer retinal degeneration (50% and 75%, respectively). The AC5(+) eyes uniquely presented outer plexiform layer (OPL) "double-layer signs" (45.8%) and "retinitis pigmentosa-like" changes (25%). Analysis of diagnostic performance revealed that "inner retinal thinning" had moderate sensitivity (66.7%) for AeNO, while "OPL double-layer signs" showed perfect specificity (100%) for AC5 within our cohort. Conclusions: This study provides valuable insights into the correlation between ARA profiles and specific OCT patterns in npAIR patients. The findings advance our understanding of npAIR pathogenesis and highlight the potential of OCT imaging and ARA profiling in the diagnosis and management of this complex condition. Financial Disclosures: The authors have no proprietary or commercial interest in any materials discussed in this article.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.